OTCMKTS:ENDV - Endonovo Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0234 0.00 (0.00 %)
(As of 02/19/2019 08:10 AM ET)
Previous Close$0.0222
Today's Range$0.02 - $0.0261
52-Week Range$0.0150 - $0.0661
Volume2.24 million shs
Average Volume3.04 million shs
Market Capitalization$11.45 million
P/E RatioN/A
Dividend YieldN/A
Endonovo Therapeutics, Inc. develops non-invasive electrocuetical devices for regenerative medicine. It is developing Electroceutical Therapy for the treatment of pain and post-surgical edema with a concentration on cosmetic surgeries, including breast augmentation, reduction and reconstruction surgery, rhinoplasty, and liposuction procedures. The company was incorporated in 2008 and is headquartered in Woodland Hills, California.

Receive ENDV News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:ENDV



Sales & Book Value

Annual SalesN/A
Book Value($0.03) per share


Net Income$-10,810,000.00


Market Cap$11.45 million
OptionableNot Optionable

Endonovo Therapeutics (OTCMKTS:ENDV) Frequently Asked Questions

What is Endonovo Therapeutics' stock symbol?

Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."

When is Endonovo Therapeutics' next earnings date?

Endonovo Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Endonovo Therapeutics.

Has Endonovo Therapeutics been receiving favorable news coverage?

Media coverage about ENDV stock has been trending positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Endonovo Therapeutics earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Endonovo Therapeutics' key competitors?

Who are Endonovo Therapeutics' key executives?

Endonovo Therapeutics' management team includes the folowing people:
  • Mr. Alan Brian Collier, Chairman, CEO, Interim CFO & Sec. (Age 53)
  • Mr. Michael Scott Mann, Pres (Age 62)
  • Mr. Donald Calabria, Chief Operating Officer
  • Mr. Steven Barnes, Sr. VP of Investor Relations
  • Bruce Garfield, Vice-Pres of Sales & Marketing

How do I buy shares of Endonovo Therapeutics?

Shares of ENDV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endonovo Therapeutics' stock price today?

One share of ENDV stock can currently be purchased for approximately $0.0234.

How big of a company is Endonovo Therapeutics?

Endonovo Therapeutics has a market capitalization of $11.45 million.

What is Endonovo Therapeutics' official website?

The official website for Endonovo Therapeutics is http://www.endonovo.com.

How can I contact Endonovo Therapeutics?

Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The biotechnology company can be reached via phone at 800-489-4774 or via email at [email protected]

MarketBeat Community Rating for Endonovo Therapeutics (OTCMKTS ENDV)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  48 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Endonovo Therapeutics and other stocks. Vote "Outperform" if you believe ENDV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel